
OKUR
Onkure Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.060
Open
2.060
VWAP
2.06
Vol
4.48K
Mkt Cap
27.56M
Low
2.060
Amount
9.23K
EV/EBITDA(TTM)
--
Total Shares
13.51M
EV
-69.10M
EV/OCF(TTM)
--
P/S(TTM)
--
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Show More
3 Analyst Rating

1297.45% Upside
Wall Street analysts forecast OKUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKUR is 28.67 USD with a low forecast of 20.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

1297.45% Upside
Current: 2.052

Low
20.00
Averages
28.67
High
34.00

1297.45% Upside
Current: 2.052

Low
20.00
Averages
28.67
High
34.00
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$40 → $34
2025-03-18
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$40 → $34
2025-03-18
Maintains
Strong Buy
Reason
Oppenheimer
Matt Biegler
Buy
Maintains
$35 → $30
2025-03-11
Reason
Oppenheimer
Matt Biegler
Price Target
$35 → $30
2025-03-11
Maintains
Buy
Reason
Oppenheimer lowered the firm's price target on OnKure Therapeutics to $30 from $35 but keeps an Outperform rating on the shares after its Q4 results. The firm's post-earnings discussion with the company revealed that an important update from PIKture-01 is slated for the second half of 2025 and should provide enough data to make a determination on OKI-219's competitive profile relative to RLY-2608 and STX-478, the analyst tells investors in a research note. While OKI-219 is ultra-selective for common H1047R mutant, the company is also being more vocal about its pan-mutant inhibitor pipeline, the firm adds.
Jones Trading
Soumit Roy
Strong Buy
Initiates
$32
2025-01-28
Reason
Jones Trading
Soumit Roy
Price Target
$32
2025-01-28
Initiates
Strong Buy
Reason
JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology company is developing targeted PI3Kalpha inhibitors for the treatment of breast cancer and other solid tumors with mutations in the PIK3CA gene, notes the analyst, who points out that this space has come under spotlight recently following the acquisition of Scorpion Therapeutics by Eli Lilly (LLY) in January for up to $2.5B. OnKure's lead asset, OKI-219, is a small molecule point-mutation specific inhibitor that targets PI3Kalpha harboring a H1047R mutation, notes the analyst, who adds that OKI-219 has "the potential to be the first approved mutation-specific PI3Kalpha inhibitor."
Leerink Partners
Andrew Berens
Buy
Initiates
$33
2024-12-05
Reason
Leerink Partners
Andrew Berens
Price Target
$33
2024-12-05
Initiates
Buy
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$40
2024-11-08
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$40
2024-11-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Initiates
$40
2024-10-17
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$40
2024-10-17
Initiates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Onkure Therapeutics Inc (OKUR.O) is -0.47, compared to its 5-year average forward P/E of -1.91. For a more detailed relative valuation and DCF analysis to assess Onkure Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.91
Current PE
-0.47
Overvalued PE
0.14
Undervalued PE
-3.97
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
108.46
Current PS
217.25
Overvalued PS
222.80
Undervalued PS
-5.88
Financials
Annual
Quarterly
FY2025Q1
YoY :
+72.92%
-17.00M
Operating Profit
FY2025Q1
YoY :
+67.00%
-15.93M
Net Income after Tax
FY2025Q1
YoY :
-96.08%
-1.19
EPS - Diluted
FY2025Q1
YoY :
+31.82%
-14.02M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
932.0
USD
2
3-6
Months
3.4M
USD
6
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
2.6M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
8.2M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
5
4.5M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
932.0
USD
2
3-6
Months
3.4M
USD
6
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
2.6M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
OKUR News & Events
Events Timeline
2025-05-06 (ET)
2025-05-06
07:32:55
OnKure Therapeutics sees cash runway into 4Q26

2025-05-06
07:32:00
OnKure Therapeutics reports Q1 EPS ($1.19), consensus ($1.38)

2025-03-10 (ET)
2025-03-10
20:49:22
OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)

Sign Up For More Events
Sign Up For More Events
News
9.5
05-06NewsfilterOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
6.0
03-11BenzingaGilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
4.0
03-10Business InsiderAnalysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)
Sign Up For More News
People Also Watch

CVGI
Commercial Vehicle Group Inc
1.760
USD
0.00%

CMTL
Comtech Telecommunications Corp
2.010
USD
0.00%

HOUR
Hour Loop Inc
1.810
USD
0.00%

HGBL
Heritage Global Inc
2.000
USD
0.00%

APLT
Applied Therapeutics Inc
0.444
USD
+4.23%

VTSI
VirTra Inc
7.000
USD
0.00%

CLIR
ClearSign Technologies Corp
0.571
USD
+1.96%

LASE
Laser Photonics Corp
2.440
USD
0.00%

MYND
Mynd.ai Inc
0.657
USD
-0.45%
FAQ

What is Onkure Therapeutics Inc (OKUR) stock price today?
The current price of OKUR is 2.0516 USD — it has increased 0.59 % in the last trading day.

What is Onkure Therapeutics Inc (OKUR)'s business?

What is the price predicton of OKUR Stock?

What is Onkure Therapeutics Inc (OKUR)'s revenue for the last quarter?

What is Onkure Therapeutics Inc (OKUR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Onkure Therapeutics Inc (OKUR)'s fundamentals?

How many employees does Onkure Therapeutics Inc (OKUR). have?
